Follicular Lymphoma Excellence Forum

Follicular Lymphoma

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Minimizing Risk of Adverse Events and Transformation Among Patients With Follicular Lymphoma

11/27/2023

Abhay Singh , MD;

Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.

Abhay Singh, MD, shares advice...

11/27/2023

Oncology

Quiz

Treating Non-Hodgkin Lymphoma With Re-Priming Radiation Therapy After CAR T

11/14/2023

True or False: Results from a phase 1 trial on re-priming radiation therapy for R/R non-Hodgkin lymphoma, including DLBCL and FL, indicated that early salvage focal definitive dose radiation to sites of incomplete response after CAR T-cell...

True or False: Results from a...

11/14/2023

Oncology

Quiz

Measuring Risk of Therapy-Related Myeloid Neoplasms Among Patients With FL or DLBCL

11/06/2023

True or False: Findings from a 15-year SEER-Medicare study identified that prior histories of autoimmunity and the use of granulocyte colony-stimulating factors significantly decreased the risk of development of therapy-related...

True or False: Findings from a...

11/06/2023

Oncology

Videos

Mitigating Risk of Transformation Among Patients With Follicular Lymphoma

10/31/2023

Kiran Kumar , MD, MBA;

Kiran Kumar, MD, MBA, discusses strategies for mitigating tumor burden and risk of transformation for patients with follicular lymphoma, particularly among those with early-stage or limited disease.

Kiran Kumar, MD, MBA, discusses...

10/31/2023

Oncology

Quiz

Epcoritamab Plus Rituximab and Lenalidomide for R/R FL

10/30/2023

True or False: The combination of epcoritamab plus rituximab and lenalidomide among patients with R/R follicular lymphoma demonstrated significantly high response rates, according to findings from the phase 1/2 EPCORE NHL-2 trial.

True or False: The combination...

10/30/2023

Oncology

Videos

Radiation Therapy for Patients With R/R Non-Hodgkin Lymphoma With Incomplete Response to CAR T-Cell Therapy

10/30/2023

Kiran Kumar , MD, MBA;

Kiran Kumar, MD, MBA, explains study results regarding the potential benefits of re-priming radiation therapy among patients with R/R non-Hodgkin lymphoma, including FL and DLBCL, who experienced incomplete response after CD19-directed CAR...

Kiran Kumar, MD, MBA, explains...

10/30/2023

Oncology

Videos

Modifying Treatment Strategies for Patients With FL or DLBCL at Risk of Therapy-Related Transformation

10/30/2023

Abhay Singh , MD;

Abhay Singh, MD, discusses the need for modifications in treatments for older patients with follicular lymphoma or DLBCL who are at risk of transformation to therapy-related myeloid neoplasms or acute myeloid leukemia.

Abhay Singh, MD, discusses the...

10/30/2023

Oncology

Quiz

Treating Follicular Lymphoma With Mosunetuzumab Monotherapy

10/24/2023

Updated results from the pivotal phase 2 GO29781 study on mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma demonstrated an overall response rate of approximately ___ among patients receiving this...

Updated results from the pivotal...

10/24/2023

Oncology

Videos

Evaluating Advances in the Treatment Landscape for Patients With Follicular Lymphoma

09/22/2023

Matthew Matasar , MD;

Matthew Matasar, MD, discusses upcoming studies and encouraging advances in the evolving treatment landscape for patients with follicular lymphoma.

Matthew Matasar, MD, discusses...

09/22/2023

Oncology

Videos

Updates on the Safety, Efficacy of Mosunetuzumab Therapy for Patients With R/R Follicular Lymphoma

09/22/2023

Matthew Matasar , MD;

Matthew Matasar, MD, shares updated results from a pivotal phase 2 study on the efficacy and safety of mosunetuzumab monotherapy among patients with relapsed/refractory follicular lymphoma.

Matthew Matasar, MD, shares...

09/22/2023

Oncology

Recent News

Commentary

Challenges of Managing FL: A Focus on PI3K Inhibitors and Next-Line Therapy

04/26/2020

Elizabeth Brem, MD, discusses some of the challenges with managing FL, focusing on the incorporation of PIK3 kinase inhibitors in the treatment of these patients.

Elizabeth Brem, MD, discusses...

04/26/2020

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology